If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Kisunla™ (donanemab-azbt) be resumed after a missed dose?
If a Kisunla (donanemab) infusion is missed, resume administration every 4 weeks at the same dose as soon as possible.
See important safety information, including boxed warning, in the attached prescribing information.
Resuming Donanemab After a Missed Dose
Administer intravenous (IV) infusions of donanemab every 4 weeks.1
If a donanemab infusion is missed, resume administration every 4 weeks at the same dose as soon as possible.1
Dose Administration in the Placebo-Controlled Studies
In the placebo-controlled studies
- dosing visits were scheduled every 4 weeks
- administration of IV infusions was allowed within ±7 days of the scheduled visit, and
- administration of IV infusions at a dosing interval of less than 21 days at any time during the study was considered a protocol deviation.2-4
Recommended Dosage and Administration
Donanemab is administered every 4 weeks as an IV infusion over approximately 30 minutes.1
The recommended dose of donanemab is 700 mg every 4 weeks for 3 doses, then 1400 mg every 4 weeks.1 Donanemab Dosing Schedule provides information on the dosing schedule.
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Mintun MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691-1704. https://doi.org/10.1056/NEJMoa2100708
3Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: February 23, 2023